car t cell therapy · 11 amaudeet al. 2018 nejm; 378(5): 439-48 bschuster et al. 2017 nejm;...
TRANSCRIPT
![Page 1: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/1.jpg)
CAR T Cell TherapyCAR T Cell Therapy
Baiyan Wang, M.D., Ph.D.
Department of Hematology
The Second Affiliated Hospital of Xi’an Jiaotong University
China
![Page 2: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/2.jpg)
2
� Editorial assistance was provided and funded by Janssen
Global Services, LLC.
Disclosures
![Page 3: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/3.jpg)
3
� What is CAR T cell therapy and how does it works?
� CAR T cell trials and approved therapies in hematological malignancies;
� Treatment approaches in Multiple Myeloma;
� CAR T cell therapies targeting BCMA in Multiple Myeloma;
Contents
![Page 4: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/4.jpg)
CAR T Cell Therapy
� What is CAR T cell therapy and how does it works?
� CAR T cell trials and approved therapies in hematological malignancies;
� Treatment approaches in Multiple Myeloma;
� CAR T cell therapies targeting BCMA in Multiple Myeloma;
![Page 5: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/5.jpg)
5
� Adoptive cell therapy that utilizes autologous T cells engineered to
express CARs
Chimeric Antigen Receptor (CAR) T Cell Therapy
Leukapheresis
T Cell
enrichment
Viral vector introduction of CAR RNA
CAR T cell
infusion
Proliferation
Patient
lymphodepletion
![Page 6: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/6.jpg)
6
� CARs consist of extracellular antigen binding domain, a transmembrane
domain, and an intracellular activation domain
CARs
Hartmann et al. 2017 EMBO Mol Med: e201607485
![Page 7: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/7.jpg)
7
ADVANTAGES
� Target specificity
� Lower potential for graft
versus host disease
� “Living drug”
� Immunotherapy/gene
therapy
Advantages and Drawbacks of CAR T Cell Therapy
DRAWBACKS
� Cytokine release syndrome (CRS)/neurotoxicity
� Relapse (hard to predict)
� Individualized manufacturing process
� Complicated chain of cost/chain of identity; logistics issue
� Cost
![Page 8: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/8.jpg)
8
� Over 400 clinical CAR T cell therapy trials registered on ClinicalTrials.gov
– ~150 in the US; ~190 in Chinaa
– China is a dominant player in the field
� Majority of CAR T cell trials are for hematologic malignancies
– ~75% of registered CAR T clinical studiesa
– 2 FDA-approved CAR T cell therapies
� CAR T cell approaches for solid tumors, autoimmune disease, and infectious
disease are also in development
– e.g., EGFRvIII for glioblastoma; HER2 for breast cancer; mesothelin for ovarian
cancer, NKG2DL for gastric caner, CD4 for HIV
Current Landscape of CAR T Cell Therapy
awww.ClinicalTrials.gov
![Page 9: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/9.jpg)
CAR T Cell Therapy
� What is CAR T cell therapy and how does it works?
� CAR T cell trials and approved therapies in hematological malignancies;
� Treatment approaches in Multiple Myeloma;
� CAR T cell therapies targeting BCMA in Multiple Myeloma;
![Page 10: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/10.jpg)
10
General Study Design of a CAR T Cell Trial
Manufacturing
(No Bridging Therapy Allowed)
Investigational Product
Hospitalization Period
Follow-up Post-treatment and
Assessment
Screening & Enrollment
Leukapheresis
Preconditioning Chemotherapya
CAR T Cell Infusion
First ResponseAssessment
acyclophosphamide; fludarabine; cyclophosphamide + fludarabine
![Page 11: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/11.jpg)
11
aMaude et al. 2018 NEJM; 378(5): 439-48bSchuster et al. 2017 NEJM; 377(26): 2545-54
� First FDA-approved CAR T cell therapy - KYMRIAH®
– CD19 CAR T cells
– Approved for acute lymphoblastic leukemia (ALL)a and diffuse large B-cell lymphoma (DLBCL)b
� ORR = 81% (ALL) and 50% (DLBCL)b
� Median EFS/PFS = not reached (ALL)a and 3.2 months (PFS for DLBCL)b
� Median OS = 19.1 months (ALL)a and 22.2 months (DLBCL)b
EFS=event-free survival; ORR=overall response rate; OS=overall survival;
PFS=progression-free survival
![Page 12: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/12.jpg)
12
� 2nd FDA-approved CD19 CAR T cell therapy - YESCARTA®
– Approved for R/R DLBCL, DLBCL arising from FL, PMBCL, high-grade B-cell lymphoma
� ORR = 82%
� Median PFS = 5.8 months
� Median OS = not reached
Neelapu et al. 2017 NEJM; 377(26): 2531-44
Complete response
ORR SD PD
All Patients (N = 101)
NE
82
11(11) 5
(5)2
(2)
54(55)
28(28)
Partial response
Stable disease
Could not be evaluated
Disease progression
FL=follicular lymphoma; R/R=relapsed/refractory;
PMBCL=primary mediastinal large B-cell lymphoma
![Page 13: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/13.jpg)
13
Kymriah® (ALL)a Kymriah® (DLBCL)a Yescarta® (DLBCL)b
All Grade Grade ≥3 All Grade Grade ≥3 All Grade Grade ≥3
CRS 79% 49% 74% 23% 94% 13%
Neurologic toxicities 72% 21% 58% 18% 87% 31%
Prolonged cytopenia
Anemia - 0% - 0% - 3%d
Neutropenia - 40%c - 25%c - 15%d
Thrombocytopenia - 27%c - 40%c - 18%d
Safety Summary of FDA-Approved CAR T Cell Therapies
aKymriah USPI; bYescarta USPI; cNot resolved by Day 28; dNot resolved by Day 30
![Page 14: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/14.jpg)
14
� CD20 for ALL, DLBCL, mantle cell lymphoma, FL, Non-Hodgkin lymphoma (NHL)
� CD22 for ALL, NHL, chronic lymphocytic leukemia, FL
� CD30 for Hodgkin lymphoma, anaplastic large cell lymphoma
� CD123 for acute myeloid leukemia
� CD138 for multiple myeloma (MM)
� B-cell maturation antigen (BCMA) for MM
Other Hematologic CAR T Cell Targets
![Page 15: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/15.jpg)
CAR T Cell Therapy
� What is CAR T cell therapy and how does it works?
� CAR T cell trials and approved therapies in hematological malignancies;
� Treatment approaches in Multiple Myeloma;
� CAR T cell therapies targeting BCMA in Multiple Myeloma;
![Page 16: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/16.jpg)
16
� Serious cancer of the bone marrow
� Incidence per year
– US: 6.1 per 100,000a
– Europe: 4.5–6.0 per 100,000b
– China: 0.6 per 100,000c
� Incurable disease
– First-line therapy will eventually encounter disease resistance leading to
disease progression
– 5-year survival rate <50%
– High unmet medical need
Multiple Myeloma
aCosta 2017 Blood Adv; 1(4): 282-7; bPalumbo 2011
Blood; 118: 4519-39; cFerlay 2012 GLOBOCAN 2012
![Page 17: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/17.jpg)
17
ESMO Guidelines for MM
Moreau et al. 2017 Ann Oncol; 28(suppl 4): iv52-61
Indolent MM Immediate treatment not recommended
<70 years Induction followed by high-dose therapy with ASCT as standard therapy
Elderly Bortezomib/melphalan/prednisone (VMP) or lenalidomide + low dose dexamethasone (Rd)
R/R MM Proteasome inhibitor- or lenalidomide-containing regimens
Advanced
CasesPomalidomide + low-dose dexamethasone and daratumumab
![Page 18: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/18.jpg)
18
� In Asia, ESMO and NCCN guidelines are used to guide treatment
� However, new drugs for patients with MM are not always available
(e.g., anti-CD38 antibody not marketed in China)
� High medical expenditures are often not covered by health insurance and
patients cannot afford to cover costs
� Differences in dosage and treatment effects in Asian and Western
populations; treatments require further optimization for Asian patients
� New treatments developed independently in China, such as CAR T cell
therapy, offer a more affordable and more accessible treatment option for
patients in Asia
MM Treatment Challenges in Asia
NCCN=National Comprehensive Cancer Network
![Page 19: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/19.jpg)
CAR T Cell Therapy
� What is CAR T cell therapy and how does it works?
� CAR T cell trials and approved therapies in hematological malignancies;
� Treatment approaches in Multiple Myeloma;
� CAR T cell therapies targeting BCMA in Multiple Myeloma;
![Page 20: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/20.jpg)
20
� Many targets available for MM:
– Integrin ẞ7, CD70, CD38, CD138, CD19, ƙ light chain, SLAMF7, and BCMA
� BCMA is an attractive target for MM
– Member of the tumor necrosis factor family
– BCMA expressed exclusively in B-cell lineages
– Involved in B-cell maturation and differentiation
– Widely expressed in malignant plasma cells
� BCMA-targeted CAR T cells are furthest in development
– BCMA CAR T – National Cancer Institute (NCI)
– bb2121 – bluebird bio
– LCAR-B38M – Nanjing Legend Biotech
CAR T Cell Approaches for MM
![Page 21: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/21.jpg)
21
� Phase 1 study of 24 patients with R/R MM
� Results from 16 patients treated at highest dose
� ORR = 81%
� 94% of patients had decrease in myeloma marker
� CRS = 94%
� Neurotoxicity = confusion and delirium
NCI BCMA CAR T
Brudno et al. 2018 JCO; 36(22): 2267-80
CD28
CD3ζ
Murine scFv
scFV=single chain variable fragment
![Page 22: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/22.jpg)
22
� Phase 1 study in 43 patients with R/R MM
� ORR = 95.5% for 22 paTents treated with ˃150x106
CAR+ T cells
� Median PFS = 11.8 months for 18 patients treated
with 150-800x106 CAR+ T cells
� CRS = 63%
� Neurotoxicity = 33%
bb-2121
Raje et al. 2018 JCO; 36(suppl): abstr 8007
4-1BB
CD3ζ
Murine scFv
![Page 23: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/23.jpg)
23
LCAR-B38M
4-1BB
CD3ζ
Llama dual-epitope
binding VHH
Other CAR T players
LCAR-B38M VHH Dual-Epitope Binding CAR
![Page 24: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/24.jpg)
24
LCAR-B38M - Efficacy
� Phase 1 study in 35 patients with R/R MM
Fan et al. 2017 JCO; 35(suppl): LBA3001 VGPR=very good partial response;
sCR=stringent complete response
Patients treated before April 5, 2017
Total PR VGPR sCR
Best response 30 2 9 19
% 100% 6.7% 30% 63.3%
![Page 25: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/25.jpg)
25
� CRS = mostly grade 1-2
� Neurotoxicity = none
� B-cell aplasia = recoverable
LCAR-B38M - Safety
Fan et al. 2017 JCO; 35(suppl): LBA3001
6
17
10
2
0 00
2
4
6
8
10
12
14
16
18
CRS
Free
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
(Death)
Cytokine Release Syndrome
Nu
mb
er
of
eve
nts
![Page 26: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/26.jpg)
26
Before CAR T Cell
Treatment
Day 19 Day 84
LCAR-B38M – Clinical Efficacy
Fan et al. 2017 JCO; 35(suppl): LBA3001
![Page 27: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/27.jpg)
27
Subject#23
2017.2.1
Before CAR T Cell Treatment 2017.4.19 2017.8.23
LCAR-B38M – Clinical Efficacy
![Page 28: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/28.jpg)
28
Cytokine Profile
Fan et al. 2017 JCO; 35(suppl): LBA3001
![Page 29: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/29.jpg)
29
� 57 patients with R/R MM have been treated with LCAR-B38M in our
institution
– Updated results will be presented at ASH 2018
� US Phase Ib/II study is ongoing and China Phase II study is planned
Current Status of LCAR-B38M
![Page 30: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/30.jpg)
30
� Allogenic CAR T cell therapy
– Universal, “off the shelf” CAR T cellsa
� Fourth generation CAR T constructs
– Inducible expression of cytokines (e.g. IL-12) within the tumor
microenvironmentb
� CRISPR gene editing technology
– Specific, directed insertion of CAR gene to T cell genomec
� Combination with other therapy
– CAR T + stem cell transplant (SCT bridging)d,e
– CAR T + targeted therapy
Future Directions for CAR T Cell Therapy
aQasim et al. 2017 Sci Transl Med; 9(374); bZhang et al. 2011 Mol Ther; 19(4): 751-9cRen et al. 2017 Oncotarget; 8: 17002-11; dMaude et al. 2017 JCO; 35(suppl): 103eChong et al. 2017 Blood; 129: 1039-41
![Page 31: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/31.jpg)
31
� CAR T cell therapy is an immunotherapy that utilizes patients’ own engineered T cells to attack cancer cells
� Promising, possibly curative treatment for some hematologic malignancies
– 2 FDA approved therapies (KYMRIAH® and YESCARTA®) for ALL and DLBCL
– BCMA-targeted CAR T therapies for MM show encouraging results
� Future of CAR T therapy:
– New generations of CAR constructs
– More specific targets for broader range of indications
– Improved manufacturing/allogenic options and universal CAR T cells
– More safety management choices
Take Home Messages
![Page 32: CAR T Cell Therapy · 11 aMaudeet al. 2018 NEJM; 378(5): 439-48 bSchuster et al. 2017 NEJM; 377(26): 2545-54 First FDA-approved CAR T cell therapy -KYMRIAH® – CD19 CAR T cells](https://reader034.vdocuments.mx/reader034/viewer/2022050217/5f63607cd401131b8e6dcf72/html5/thumbnails/32.jpg)
32
Nanjing Legend Biotech Co.Nanjing Legend Biotech Co.The Second Affiliated Hospital of
Xi’an Jiaotong University
The Second Affiliated Hospital of
Xi’an Jiaotong University
Acknowledgments